Gennex Laboratories Limited has fulfilled its regulatory obligations by publishing its unaudited financial results for the quarter and nine months ended December 31, 2025, in newspapers as mandated under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Regulatory Compliance and Publication Details

The company submitted the newspaper publication notice to multiple stock exchanges on February 17, 2026, including BSE Limited (Script Code: 531739), The Ahmedabad Stock Exchange Limited, and The Calcutta Stock Exchange Limited (Scrip Code: 26178). The financial results were published in both Business Standard (English) and Saksham (Telugu - Local) newspapers on Monday, February 16, 2026.

Financial Performance Overview

The unaudited financial results cover both standalone and consolidated figures for the quarter and nine months ended December 31, 2025. These results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on Saturday, February 14, 2026.

Consolidated Results

The consolidated financial results show the company's performance including its subsidiaries. For the quarter ended December 31, 2025, consolidated total income reached ₹10,379.92 thousands compared to ₹4,295.61 thousands in the corresponding quarter of the previous year.

Corporate Governance and Compliance

The financial results were prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act, 2013. The results have been subjected to limited review by the company's statutory auditors. The company maintains an equity share capital of ₹2,428.48 thousands with a face value of ₹1 per share.

Management and Authorization

The newspaper publication was authorized by Dinesh Kumar Kejriwal, Company Secretary & Compliance Officer (Membership #A19293), and digitally signed on February 17, 2026. The financial results were signed by Arthit Baid, Managing Director (DIN: 01171845), confirming the company's adherence to corporate governance standards.

The complete detailed format of the quarterly financial results is available on the websites of stock exchanges including BSE ( www.bseindia.com ) and on the company's official website ( www.gennexlab.com ) for stakeholder reference.

Source:

Gennex Laboratories has announced the resignation of Ms. Shilpa Bung from her position as Non-Executive Independent Women Director, effective February 14, 2026. The resignation was tendered with immediate effect and was formally accepted by the Board of Directors during their meeting held on the same date.

Reason for Resignation

Ms. Bung's decision to step down stems from her recent election as Chairperson of the CS Hyderabad Chapter. In her resignation letter, she explained that this new leadership position demands significant time commitment and responsibilities that would preclude her continued active participation on Gennex Laboratories' Board.

Director Details and Compliance

Ms. Bung has confirmed that there are no other material reasons for her resignation beyond those mentioned in her resignation letter, as required under regulatory guidelines.

Other Directorships

The departing director currently holds independent director positions in two other listed entities:

• Sigachi Laboratories Limited
• Godavari Drugs Limited

Ms. Bung has also requested to be relieved from all Board Committees of which she was a member.

Regulatory Compliance

The resignation has been reported in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has fulfilled all necessary disclosure requirements and uploaded the intimation on its website at www.gennexlab.com .

In her resignation letter, Ms. Bung expressed gratitude to the Board and management for the opportunity to serve and contribute to the company's growth during her tenure as Independent Director.